NIH PAR · NINDS · R61, R33

PAR-25-225: Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards

Open for applicationsNext due date: Oct 20, 2026Expires Oct 21, 2027

Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.

Full NOFO in the NIH Guide Apply on Grants.gov

NOFO number
PAR-25-225
Type
PAR
Activity code
R61R33
Primary institute
NINDS · National Institute of Neurological Disorders and Stroke
Clinical trials
Not Allowed
Posted
Nov 4, 2024
Opens
Jan 19, 2025
Expires
Oct 21, 2027

PAR-25-225 due dates

4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.

Application due dates and review cycles for PAR-25-225
Application Due Date(s)Renewal / Resubmission / Revision (as allowed)AIDS - New/Renewal/Resubmission/Revision, as allowedScientific Merit ReviewAdvisory Council ReviewEarliest Start Date
February 18, 2025February 18, 2025Not ApplicableJuly 2025October 2025December 2025
June 18, 2025June 18, 2025Not ApplicableNovember 2025January 2026April 2026
October 20, 2025October 20, 2025Not ApplicableMarch 2026May 2026July 2026
February 18, 2026February 18, 2026Not ApplicableJuly 2026October 2026December 2026
June 18, 2026June 18, 2026Not ApplicableNovember 2026January 2027April 2027
October 20, 2026October 20, 2026Not ApplicableMarch 2027May 2027July 2027
February 18, 2027February 18, 2027Not ApplicableJuly 2027October 2027December 2027
June 18, 2027June 18, 2027Not ApplicableNovember 2027January 2028April 2028
October 20, 2027October 20, 2027Not ApplicableMarch 2028May 2028July 2028

Projects funded under PAR-25-225

NIH RePORTER lists 8 projects funded under PAR-25-225 in FY2022–FY2026, with $3.4M in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.

Projects funded

8

Distinct projects, FY2022–FY2026

New awards

8

Type 1 (new project) award records

NIH funding

$3.4M

Award dollars under PAR-25-225, FY2022–FY2026

Funding by fiscal year

Award records, new awards, and funding by fiscal year under PAR-25-225
Fiscal yearAward recordsNew awardsFunding
FY202200$0
FY202300$0
FY202400$0
FY202500$0
FY202688$3.4M

Institutions with the most funding

  1. University of Florida$766K · 2 projects
  2. Johns Hopkins University$581K · 1 project
  3. Mayo Clinic Rochester$501K · 1 project
  4. University of Minnesota$487K · 1 project
  5. Loyola University Chicago$342K · 1 project

Funding institutes

  • NINDS$3.4M · 8

Activity codes funded

  • R618 records

FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.

Participating institutes

2 NIH institutes and offices take applications under PAR-25-225. Contact the program officer at the institute that fits your research before applying.

  • NINDS · National Institute of Neurological Disorders and Stroke
  • none

Related notices

  1. Mar 31, 2025 · NOT-OD-24-084

    This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…

  2. Aug 31, 2022 · NOT-OD-22-198

    Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.

  3. Aug 5, 2022 · NOT-OD-22-189

    Implementation Details for the NIH Data Management and Sharing Policy.

Award terms

Application types allowed
NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
Award budget
Direct costs cannot exceed 499,000 in any one year. Cumulative direct costs for the entire three-year project period may not exceed 750,000.
Project period
The total project period for a combined R61/R33 application submitted in response to this NOFO may not exceed three years, with no more than two years for the R61 phase and no more than two years for the R33 phase. For example, a project could have a 1-year R61 and a 2-year R33 or could have a 2-year R61 and a 1-year R33.) NIH grants policies as described in the NIH Grants Policy Statement will…
Funds available and number of awards
The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.

Related NOFOs

Other open NOFOs for R61, R33

Browse all open NIH NOFOs

About this page

GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.

Find who wins under this NOFO